Sonnet BioTherapeutics（納斯達克股票代碼：SONN）報告季度每股虧損$(1.56)，不及分析師一致預期的$(1.39)，差距爲12.23%。較去年同期每股虧損$(2.46)相比，虧損減少36.59%。

以上內容來自Benzinga Earnings專欄，原文如下：

Sonnet BioTherapeutics (NASDAQ:SONN) reported quarterly losses of $(1.56) per share which missed the analyst consensus estimate of $(1.39) by 12.23 percent. This is a 36.59 percent increase over losses of $(2.46) per share from the same period last year.